Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.01)
# 2,984
Out of 4,944 analysts
111
Total ratings
36.36%
Success rate
-6.1%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Maintains: Buy | $15 | $4.29 | +249.65% | 4 | Aug 1, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $9.60 | +181.25% | 6 | Jul 29, 2025 | |
| ATAI Atai Life Sciences | Maintains: Buy | $12 → $11 | $4.05 | +171.60% | 3 | Jul 28, 2025 | |
| CYBN Cybin | Maintains: Buy | $73 → $70 | $7.60 | +821.05% | 8 | Jul 8, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $26 → $17 | $2.70 | +529.63% | 3 | May 15, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $158 → $160 | $131.61 | +21.58% | 16 | May 6, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $135.19 | +62.73% | 21 | May 2, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $9.43 | +165.11% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $3.66 | +227.87% | 5 | Mar 13, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $112 → $80 | $5.60 | +1,328.57% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $12.65 | +121.34% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $83 | $3.65 | +2,173.97% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $9.97 | +40.42% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $16.91 | +18.27% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $25.13 | +31.32% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $14.39 | +942.39% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $17.21 | - | 2 | Jan 31, 2017 |
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $4.29
Upside: +249.65%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $9.60
Upside: +181.25%
Atai Life Sciences
Jul 28, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $4.05
Upside: +171.60%
Cybin
Jul 8, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $7.60
Upside: +821.05%
Annovis Bio
May 15, 2025
Maintains: Buy
Price Target: $26 → $17
Current: $2.70
Upside: +529.63%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158 → $160
Current: $131.61
Upside: +21.58%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $135.19
Upside: +62.73%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $9.43
Upside: +165.11%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.66
Upside: +227.87%
BioXcel Therapeutics
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $5.60
Upside: +1,328.57%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $12.65
Upside: +121.34%
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $3.65
Upside: +2,173.97%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $9.97
Upside: +40.42%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $16.91
Upside: +18.27%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $25.13
Upside: +31.32%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $14.39
Upside: +942.39%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $17.21
Upside: -